SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 17, 2022 | Series A | $26M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Cancer Research Institute | — | Series A |